Riddet Institute, Massey University, Palmerston North, New Zealand.
Program of Applied Science and Technology, Center for Excellence in Post-Harvest Technologies, North Carolina Agricultural and Technical State University, North Carolina Research Campus, Kannapolis, North Carolina, USA.
Crit Rev Food Sci Nutr. 2022;62(9):2470-2494. doi: 10.1080/10408398.2020.1854169. Epub 2020 Nov 30.
Oral administration of live probiotics along with prebiotics has been suggested with numerous beneficial effects for several conditions including certain infectious disorders, diarrheal illnesses, some inflammatory bowel diseases, and most recently, irritable bowel syndrome. Though, delivery of such viable bacteria to the host intestine is a major challenge, due to the poor survival of the ingested probiotic bacteria during the gastric transit, especially within the stomach where the pH is highly acidic. Although microencapsulation has been known as a promising approach for improving the viability of probiotics in the human digestive tract, the success rate is not satisfactory. For this reason, co-encapsulation of probiotics with probiotics has been practised as a novel alternative approach for further improvement of the oral delivery of viable probiotics toward their targeted release in the host intestine. This paper discusses the co-encapsulation technologies used for delivery of probiotics toward better stability and viability, as well the incorporation of co-encapsulated probiotics and prebiotics in functional/synbiotic dairy foods. The common encapsulation technologies (and the materials) used for this purpose, the stability and survival of co-encapsulated probiotics in the food, and the release behavior of the co-encapsulated probiotics in the gastrointestinal tract have also been explained. Most studies reported a significant improvement particularly in the viability of bacteria associated with the presence of prebiotics. Nevertheless, the previous research has mostly been carried out in the simulated digestion, meaning that future systematic research is to be carried out to investigate the efficacy of the co-encapsulation on the survival of the bacteria in the gut in vivo.
口服益生菌联合益生元已被证实对多种疾病具有有益作用,包括某些感染性疾病、腹泻病、某些炎症性肠病,以及最近的肠易激综合征。然而,由于摄入的益生菌在胃转运过程中(特别是在胃酸度高的胃部)的存活率低,将这些活菌递送到宿主肠道是一个主要挑战。虽然微胶囊化已被认为是提高益生菌在人体消化道中存活率的一种有前途的方法,但成功率并不理想。因此,将益生菌与益生菌共同包封已被实践为一种新的替代方法,以进一步提高活菌益生菌的口服递送效果,使其在宿主肠道中靶向释放。本文讨论了用于益生菌递送的共同包封技术,以提高稳定性和存活率,以及将共同包封的益生菌和益生元纳入功能性/共生乳制品中的方法。本文还解释了用于此目的的常见包封技术(和材料)、共同包封益生菌在食品中的稳定性和存活率,以及共同包封益生菌在胃肠道中的释放行为。大多数研究报告称,益生菌的存活率显著提高,特别是在存在益生元的情况下。然而,以前的研究大多是在模拟消化条件下进行的,这意味着未来需要进行系统研究,以调查共同包封对益生菌在体内肠道中存活的效果。
Crit Rev Food Sci Nutr. 2022
Adv Colloid Interface Sci. 2022-11
Nutrients. 2017-9-15
Crit Rev Biotechnol. 2021-9
Probiotics Antimicrob Proteins. 2025-6-23
J Microbiol Biotechnol. 2025-6-12
Front Microbiol. 2025-1-6